Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Centers for Disease Control and Prevention The Miriam Hospital Minneapolis Medical Research Foundation Washington University School of Medicine Denver Infectious Disease Consultants, PLLC |
---|---|
Information provided by: | Centers for Disease Control and Prevention |
ClinicalTrials.gov Identifier: | NCT00146419 |
The SUN Study is a Centers for Disease Control and Prevention (CDC)-sponsored multi-site prospective observational cohort study designed to better understand the incidence and etiology of metabolic and other complications related to effective HIV treatment and longer survival. The SUN Study is also providing a platform to evaluate a behavioral intervention designed to reduce HIV transmission through prevention counseling in routine care.
Condition | Intervention |
---|---|
HIV Infections Sexually Transmitted Diseases |
Behavioral: Reduction in behaviors capable of sexually transmitting HIV |
Study Type: | Observational |
Study Design: | Natural History, Longitudinal, Defined Population, Prospective Study |
Official Title: | Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) |
Estimated Enrollment: | 1000 |
Study Start Date: | March 2004 |
Effective antiretroviral therapy has significantly improved and prolonged the lives of HIV-infected persons. However, antiretroviral use has also been associated with a diverse array of “unnatural” metabolic complications and other adverse medical conditions. These problems, together with subsequent longer survival, have increased patients’ risk for developing renal, hepatic, cardiovascular, neurological, rheumatologic, and other end-organ diseases, and cancers. Longer survival is also increasing the pool of HIV-infected persons capable of transmitting the virus, which could accelerate the pace of the U.S. epidemic; however, the ability of physicians caring for HIV-infected persons to incorporate prevention into their clinical practices and the effectiveness of this intervention have not been extensively evaluated.
The goals of the Study to Understand the Natural History of HIV and AIDS (“SUN” Study) are:
The SUN Study is designed to enroll and follow for 5 or more years a cohort of up to 1,000 HIV-infected adults at HIV specialty care centers in four U.S. cities: Denver, Minneapolis, Providence, and St. Louis. Data will be gathered through longitudinal real-time chart review, biannual physical examination (e.g., body mass index [BMI], blood pressure), repeated non-invasive imaging (e.g., dual energy x-ray absortiometry [DEXA] scanning, carotid ultrasonography) and regularly scheduled laboratory testing (e.g., serum lipids, pap smears, and urinary microalbumin). Data collection and quality control will be managed by Cerner Corporation. After sufficient enrollment, (circa 200 persons per site) a structured prevention program to reduce HIV transmission will be introduced. The impact of this intervention will be evaluated both subjectively (e.g., self-reported change in behavior on an audio computer-assisted self-interviewing [ACASI] questionnaire) and objectively (e.g., change in sexually transmitted disease [STD] incidence).
Outcomes include determination of the incidence of therapy-related metabolic complications and other adverse conditions associated with longer survival, identification of risk factors for these complications and conditions, and reduction in both reported and objective measures of risky sexual behavior.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
For highly active antiretroviral therapy (HAART)-naïve subjects (i.e. persons with no prior substantial antiretroviral [ARV] exposure):
For HAART-exposed subjects (i.e. persons who have taken or are taking HAART at the time of enrollment):
Subject’s previous and/or current treatment with ARVs has consisted only of HAART (of any duration and in any number of regimens) defined as:
Exclusion Criteria:
Within the past 60 days subject has:
Footnotes:
Contact: John T Brooks, M.D. | 404-639-3894 | zud4@cdc.gov |
United States, Colorado | |
Denver Infectious Disease Consultants | Recruiting |
Denver, Colorado, United States, 80220 | |
Contact: John H Hammer, M.D. 303-393-8050 hammer_john@msn.com | |
Principal Investigator: John H Hammer, M.D. | |
University of Colorado Health Sciences Center | Recruiting |
Denver, Colorado, United States, 80220 | |
Contact: Ken Lichtenstein, M.D. 303-320-2830 didc.kal@juno.com | |
Principal Investigator: Ken Lichtenstein, M.D. | |
United States, Minnesota | |
Hennepin County Medical Center | Recruiting |
Minneapolis, Minnesota, United States, 55404 | |
Contact: Keith Henry, M.D. 612-873-7516 keithh6680@aol.com | |
Principal Investigator: Keith Henry, M.D. | |
Abbott Northwestern Hospital | Recruiting |
Minneapolis, Minnesota, United States, 55407 | |
Contact: Frank Rhame, M.D. 612-325-9520 frank@muskie.bios.umn.edu | |
Principal Investigator: Frank Rhame, M.D. | |
Park-Nicollet Institute | Recruiting |
Minneapolis, Minnesota, United States, 55416 | |
Contact: Hal Martin, M.D. 952-993-3131 martinh@parknicollet.com | |
Principal Investigator: Hal Martin, M.D. | |
United States, Missouri | |
Washington University School of Medicine | Recruiting |
St. Louis, Missouri, United States, 63108 | |
Contact: Kristin Mondy, M.D. 314-289-6433 kristinmd@swbell.net | |
Contact: Turner Overton, M.D. 314-454-0058 toverton@im.wustl.edu | |
Principal Investigator: Kristin Mondy, M.D. | |
Sub-Investigator: Turner Overton, M.D. | |
United States, Rhode Island | |
The Miriam Hospital | Recruiting |
Providence, Rhode Island, United States, 02905 | |
Contact: Charles Carpenter, M.D. 401-793-4025 ccjc@lifespan.org | |
Contact: Milu Kojic, M.D. 401-793-5961 ekojik@lifespan.org | |
Sub-Investigator: Susan Cu-Uvin, M.D. | |
Sub-Investigator: Kenneth H Mayer, M.D. | |
Principal Investigator: Charles Carpenter, M.D. | |
Sub-Investigator: Milu Kojic, M.D. | |
United States, Virginia | |
Cerner Corporation | Recruiting |
McLean, Virginia, United States, 22182 | |
Contact: Kathy Wood, R.N. 703-587-9231 kwood@cerner.com | |
Principal Investigator: Kathy Wood, R.N. | |
Sub-Investigator: Rose Baker, M.S. |
Principal Investigator: | Charles Carpenter, M.D. | The Miriam Hospital |
Principal Investigator: | Keith Henry, M.D. | Minneapolis Medical Research Foundation |
Principal Investigator: | Kristin Mondy, M.D. | Washington University School of Medicine |
Principal Investigator: | John H Hammer, M.D. | Denver Infectious Disease Consultants, PLLC |
Study ID Numbers: | CDC-NCHSTP-3979, 200-2002-00610, 200-2002-00611, 200-2002-00612, 200-2002-00613 |
Study First Received: | September 1, 2005 |
Last Updated: | January 3, 2006 |
ClinicalTrials.gov Identifier: | NCT00146419 |
Health Authority: | United States: Federal Government |
Treatment Experienced Treatment Naive |
Genital Diseases, Female Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Acquired Immunodeficiency Syndrome |
Sexually Transmitted Diseases Genital Diseases, Male Retroviridae Infections Immunologic Deficiency Syndromes |
RNA Virus Infections Slow Virus Diseases Immune System Diseases Lentivirus Infections Infection |